Study: How Ketamine Changes Chronic PTSD Patient’s Brain Neurochemistry
Last reviewed and updated: June 26, 2026.
Key Takeaways
| Ketamine PTSD mechanism | NMDA antagonism → glutamate burst → BDNF release → neuroplasticity in amygdala, hippocampus, prefrontal cortex; works in hours vs. weeks for SSRIs |
| Speed of action | Rapid relief within hours — clinically critical for suicidal PTSD patients who cannot wait weeks for antidepressant response |
| MDMA PTSD context | FDA rejected MDMA-assisted therapy 2024 (methodological concerns) — making ketamine more strategically important as an available bridge treatment |
| Ibogaine PTSD (Stanford 2024) | Nature Medicine study: 88% symptom reduction, 67% no longer met PTSD criteria at 1 month in veterans — different mechanism, complementary evidence |
| Spravato PTSD path | Phase 3 PTSD data exists; label expansion possible — would dramatically increase insurance coverage and mainstream prescribing for PTSD |
Ketamine, which has long been used as an anesthetic and recreational drug, receives more attention nowadays for its therapeutic applications. Ketamine-assisted therapy (ketamine sessions combined with psychotherapy) seems especially useful in the treatment of depression. This includes the types that are treatment-resistant or which feature suicidality.
RELATED: How Do You Treat PTSD with Ketamine? Clinicians Weigh In
Ketamine For PTSD
Like classic psychedelics, ketamine also seems to benefit people with various forms of emotional distress. These include:
- Bipolar disorder
- Anxiety
- Obsessive-compulsive disorder (OCD)
- Drug and alcohol addiction
- Post-traumatic stress disorder (PTSD)
A new brain imaging study, published in the journal Neuropsychopharmacology, suggests how ketamine may help those living with chronic PTSD.
PTSD is a type of anxiety disorder, affecting about 12 million adults in the U.S. during a given year. Six percent of the population will have PTSD at some point in their lives. In some individuals, though, that condition can be severe, chronic, and treatment-resistant. In these cases, the symptoms can be highly distressing and interfere with work, relationships, and everyday activities. These symptoms include intrusive memories related to the trauma and negative changes to thinking, mood, and emotional reactions.
When conventional treatments (psychiatric medication and psychotherapy) fail, ketamine can sometimes help. However, how the drug actually benefits people has not been clear. The experience itself may play a significant role, which seems to apply in the case of classic psychedelics.
Researchers believe that the way ketamine alters the brain — in terms of neurochemistry and brain region activity — matters, too. Ketamine may restore brain regions (and connections between them) affected by depression to a normal level of activity. And the same could apply in the case of PTSD and other conditions as well.
How Ketamine Alters The Brain In People With Chronic PTSD
This new study published in Neuropsychopharmacology, led by Adriana Feder, M.D., suggests improvements in PTSD following ketamine are related to specific changes in connectivity between several brain regions.
Feder and a team of researchers analyzed detailed brain imaging data of individuals with chronic PTSD. Each patient had been treated with ketamine in a randomized clinical trial. The trial was small, involving 30 chronic PTSD patients with moderate to severe symptoms.
Half of the participants received six ketamine infusions over a period of two weeks. The other half received infusions of the psychoactive placebo control drug midazolam. Both of these drugs act as anesthetics. However, in the trial, they were both given at sub-anesthetic doses.
RELATED: How Psychedelics Helped Hockey Player, Pro Fighters (and Me!) Heal from a Traumatic Brain Injury
The trial was fully blind, so neither the participants nor the researchers knew which drug participants were randomly given.
Feder and colleagues had published previous research showing that repeated ketamine infusions over a two-week period significantly reduced PTSD symptoms in many participants while also reducing depression symptoms that often accompany PTSD.
The control drug from the study (which has anti-anxiety effects) also alleviated PTSD symptoms in some patients, but not to the same degree as ketamine.
RELATED: Here’s Why Ketamine Is Different Than Any Other Psychedelic
How The Study Was Conducted
In this new paper, the team analyzed brain imaging data from 21 of the 30 trial participants, drawing upon data from two scanning sessions: One carried out before the trial began, the other after most or all of the infusions were administered. This data allowed the team to identify “neural correlates” — changes in brain activity following the infusion of ketamine or the control drug.
The brain imaging sessions included scans made while participants were asked to respond to a computer monitor displaying faces depicting various emotions. The researchers also conducted a scan while participants were “at rest” — when they weren’t performing any task.
Irrespective of the drug given, improvements in PTSD symptom severity were related to connectivity changes between brain regions found to show abnormal activity in people with PTSD. These included two cortical areas: the ventromedial prefrontal cortex (vmPFC) and the dorsal/rostral anterior cingulate cortex (d/rACC), as well as emotion-processing areas including the amygdala and the anterior section of the insula.
The changes in connectivity in these areas were seen mainly when participants responded to “emotional faces” during the scanning sessions. More specifically, faces that were ambiguous or neutral, and those that displayed negative emotions, such as fear.
Results From The Ketamine For PTSD Study
The team suggests that there is a drug-specific mechanism that leads to changes in connectivity between the vmPFC and amygdala. Improvements in symptoms with both drugs were correlated with decreased excitation of circuitry from the amygdala to the vmPFC when participants viewed the emotional faces.
The vmPFC helps us make decisions based on information gathered from connections to the amygdala. It often involves controlling and regulating emotional experiences. Normally, it keeps the amygdala in check, allowing us to regulate stress, anxiety, and anger. This helps us to avoid feeling overwhelmed by our emotions.
In conditions like PTSD and depression, regions of the prefrontal cortex are underactive, while the amygdala is overactive.
By altering the connections between the vmPFC and the amygdala, ketamine can reduce PTSD symptoms like hypervigilance and hyperarousal. The ability of the vmPFC to restrain emotional responses can return, in other words.
Indeed, in Feder’s study, this connectivity change was only seen in participants with a decrease in symptoms following ketamine treatments. Ketamine increased “top-down” inhibition of the amygdala, exerted by the vmPFC.
Therefore, the team proposes that a reduction in the intensity of the threat response and/or an enhancement of learning to extinguish memory-based fear responses may be driving these decreases in PTSD symptom severity following ketamine treatment. Ketamine led to a greater response rate as well as a longer time — on average — to relapse. This might be due to ketamine’s ability to increase neural plasticity in brain regions linked to chronic symptoms.
The Benefits Of Using Ketamine Alongside Psychotherapy
If less intense threat and fear responses contribute to ketamine-related improvements in PTSD symptoms, Feder suggests combining ketamine treatment with psychotherapy might be especially beneficial. This is because many forms of psychotherapy help people with fear extinction learning (the lessening of conditioned fear responses following exposure to material that is normally distressing).
According to the team, ketamine-assisted psychotherapy could “‘open a window’ for the relearning of ingrained cognitive biases or maladaptive fear memories” associated with persistent PTSD symptoms.
See also: — our ketamine therapy resources.
Ketamine’s PTSD Evidence Base in 2024–2026: Why This Research Matters More Now
The neurochemical findings described in the study above did not emerge in a vacuum — and they land in a 2024–2026 clinical landscape that has made ketamine’s evidence base for PTSD more strategically important than it was when this research was first published. The PTSD treatment field has gone through a significant shift, and understanding where ketamine fits requires understanding that context.
The MDMA rejection and its implications for ketamine. In August 2024, the FDA rejected Lykos Therapeutics’ application for MDMA-assisted psychotherapy for PTSD — the most closely watched PTSD drug application in years. The rejection was methodological (functional unblinding, population generalizability) rather than a finding of inefficacy, but it removed MDMA from the near-term treatment pipeline. For the approximately 13 million Americans currently experiencing PTSD, this matters: the widely anticipated “next generation” PTSD treatment is now years away from approval at minimum. That makes ketamine and Spravato more central as bridge treatments and as evidence-backed alternatives for patients who have failed first-line approaches like SSRIs and trauma-focused therapy. Ketamine does not require a Phase 3 approval process — it is already in clinical use, and the neurochemical mechanisms documented in studies like this one help explain why it works as quickly as it does.
Ibogaine enters the data picture. A 2024 Stanford study published in Nature Medicine added a striking new data point to the PTSD neuroscience landscape. Researchers gave a single dose of ibogaine (combined with magnesium for cardiac safety) to 30 special operations veterans with severe PTSD — a population that had failed multiple prior treatments. At one month follow-up, PTSD symptom scores had dropped by 88% on average, with 67% no longer meeting PTSD diagnostic criteria. These are remarkable numbers for a single-session intervention, and the mechanism appears complementary to ketamine’s: while ketamine works through the glutamate/NMDA system and produces neuroplasticity effects over hours to days, ibogaine appears to work through a complex multi-receptor profile that includes 5-HT2A agonism, sigma receptor effects, and its own neuroplasticity-promoting properties. The convergence of evidence suggests PTSD may respond to multiple neurobiological pathways — glutamate-targeting (ketamine), serotonin-targeting (psilocybin), and ibogaine’s multi-target profile — potentially reflecting different PTSD subtypes that respond to different mechanisms.
Spravato’s PTSD trajectory and what’s ahead. Spravato (esketamine) is currently FDA-approved for treatment-resistant depression and major depressive disorder with suicidal ideation — not specifically for PTSD, even though ketamine’s PTSD mechanism is one of its most compelling clinical stories. Janssen has conducted Phase 3 trials examining Spravato for PTSD, and the data is promising. A label expansion specifically for PTSD would be a significant milestone that would dramatically increase insurance coverage and mainstream prescribing. The current trajectory — multiple converging lines of evidence for glutamate-targeting drugs in PTSD, growing political support (April 2026 executive order naming ketamine and related compounds as veteran PTSD research priorities), and the post-MDMA-rejection void in the near-term pipeline — points toward ketamine occupying an increasingly important role in PTSD care between now and when the next generation of psychedelic medicines becomes clinically available.
Frequently Asked Questions
How does ketamine help PTSD?
Ketamine helps PTSD through its effects on the glutamate system — specifically by blocking NMDA receptors, which triggers a cascade of neurobiological effects that matter for PTSD specifically. The NMDA block causes a rapid surge of glutamate activity in other pathways, which stimulates AMPA receptors and triggers the release of brain-derived neurotrophic factor (BDNF) — a protein that promotes synaptic growth and neuroplasticity. In the context of PTSD, this matters because the condition is associated with atrophy in key brain regions including the hippocampus (memory consolidation) and prefrontal cortex (emotional regulation), and with dysregulated amygdala activity (fear processing). Ketamine’s rapid neuroplasticity effects appear to reverse some of these structural and functional changes, potentially helping the brain “rewire” away from chronic hypervigilance and fear responses. This is also why ketamine works within hours rather than the weeks required by SSRIs — it targets neuroplasticity directly rather than waiting for the gradual serotonergic adaptations that underlie antidepressant effects.
Is ketamine FDA-approved for PTSD?
IV ketamine is not FDA-approved for PTSD — it is prescribed off-label, which is legal but means insurance typically does not cover it. Spravato (esketamine nasal spray) is FDA-approved for treatment-resistant depression and major depressive disorder with suicidal ideation, but not currently for PTSD. However, Janssen (Spravato’s manufacturer) has conducted Phase 3 trials examining Spravato specifically for PTSD, and a label expansion is plausible given the evidence. Many ketamine clinics treat PTSD as an off-label indication, and psychiatrists can prescribe IV ketamine for PTSD without FDA approval. The current situation: clinically available and used, not yet formally approved specifically for PTSD. Approval for Spravato in PTSD would be the next major regulatory milestone in this space.
How does ketamine compare to MDMA for PTSD?
Ketamine and MDMA represent different approaches to PTSD with different mechanistic rationales and very different regulatory statuses. MDMA-assisted psychotherapy works by reducing amygdala hyperreactivity and releasing oxytocin during 8-hour therapy sessions, creating a window in which patients can process traumatic material with reduced fear response — the therapeutic work happens during the session. Ketamine works through NMDA antagonism and neuroplasticity promotion, producing rapid antidepressant and anxiolytic effects that persist for days to weeks after shorter sessions; the mechanism is more pharmacological than session-based. MDMA’s application for PTSD was rejected by the FDA in 2024 (methodological concerns, not efficacy); ketamine and Spravato are legally available now. From a practical standpoint, ketamine is the available option for patients who need treatment today, while MDMA-assisted psychotherapy — if its regulatory path is resolved — may offer a complementary approach targeting the trauma processing more directly.
What does “neuroplasticity” mean for PTSD recovery?
Neuroplasticity refers to the brain’s ability to change its structure and function — to form new synaptic connections, strengthen or weaken existing pathways, and reorganize in response to experience. PTSD is associated with measurable neurobiological changes: reduced hippocampal volume, hyperactive amygdala responses, and weakened prefrontal control over fear responses. These changes maintain the PTSD cycle — the brain has been structurally shaped by trauma to remain on high alert. Treatments that promote neuroplasticity — including ketamine (BDNF release, synaptic growth), psilocybin (also promotes BDNF and synaptogenesis), and trauma-focused therapy (which changes neural patterns through repeated processing) — offer a pathway to reversing these structural changes rather than just managing symptoms. Ketamine’s neuroplasticity effects happen rapidly (within hours to days), which helps explain both its speed of action and why some patients need repeated infusions to maintain effects — the brain needs time to consolidate the new patterns being enabled by the drug.
